Abeona Buys Phase 3-Ready APT-1011 as ABO-801, Lands $30M Private Placement
ABEO is trading near its 52-week low of $3.91 (6.9% above the low).
Summary
Abeona is adding a second late-stage asset: it acquired APT-1011, a Phase 3-ready program it will now call ABO-801, for $20 million in equity consideration at closing with no upfront cash payment, and simultaneously signed a $30 million private placement that includes leading life sciences investors. That cash is meaningful against a company that ended Q2 2026 with $146.8 million in cash and is still funding the ZEVASKYN launch, where treated patients rose from five at the Q2 report to 12 by late September. The deal broadens the pipeline beyond ZEVASKYN and the Sanfilippo program Ultragenyx took through FDA approval in September, reducing single-asset dependence. Terms of the placement — price per share and discount to the $4.18 market price — are not in the headline and will determine how dilutive this actually is. Watch the 8-K and placement pricing details for the real read on dilution and on who is funding the company.
At the time of this announcement, ABEO was trading at $4.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $238.5M. The 52-week trading range was $3.91 to $7.65. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.